Table 3.
Results from multivariable logistic regression of BRCA1/2 deficiency
| Number of patients | Number BRCA1 / 2 deficient | P value | OR (95% CI) | |
|---|---|---|---|---|
| HRD-Mean score | 186 | 34 | 1.2 × 10-16 | 87 (17, 450) |
| Age at diagnosis | 186 | 34 | 0.027 | 0.95 (0.91, 1.0) |
| Stage | 0.63 | |||
| I | 12 | 3 | 1 | |
| II | 119 | 22 | 2.4 (0.22, 27) | |
| III | 52 | 8 | 0.99 (0.073, 13) | |
| IV | 3 | 1 | 3.1 (0.0011, 9100) | |
| Gradea | 0.40 | |||
| 1 | 17 | 0 | 1 | |
| 2 | 99 | 14 | ∞ (0, ∞) | |
| 3 | 70 | 20 | ∞ (0, ∞) | |
| Subtype | 0.087 | |||
| TNBC | 44 | 19 | 3.9 (0.62, 24) | |
| ER –/HER2 + | 34 | 3 | 1 | |
| ER +/HER2 – | 48 | 5 | 0.39 (0.039, 3.8) | |
| ER +/HER2 + | 60 | 7 | 1.3 (0.16, 10) |
Odds ratio for the HRD-Mean score is reported per interquartile range of the score. The odds ratio for age at diagnosis is reported per year. This analysis includes 186 patients with complete clinical records. Thirty-four patients were BRCA1 or BRCA2 deficient. CI, confidence interval; ER, estrogen receptor; HER2, tyrosine kinase-type cell surface receptor HER2; HRD-Mean, mean of the homologous recombination deficiency-loss of heterozygosity, homologous recombination deficiency-large-scale state transition, and homologous recombination deficiency-telomeric allelic imbalance scores; OR, odds ratio; TNBC, triple-negative breast cancer. aThe odds ratio for grade is inestimable due to zero BRCA1/2-deficient grade 1 tumors.